Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy

Pharmacogenomics Journal

Volumn 14, Issue 2, 2014, Pages 135-141

  Benhaim, L ^a,b   Gerger, A ^a   Bohanes, P ^a   Paez, D ^a   Wakatsuki, T ^a   Yang, D ^a   Labonte, M J ^a   Ning, Y ^a   El Khoueiry, R ^a   Loupakis, F ^a   Zhang, W ^a   Laurent Puig, P ^b   Lenz, H J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b INSERM   (France)

Author keywords

Colorectal cancer; Gender; Polymorphism; SCN1A; VGSC; Voltage gated sodium channels

Indexed keywords

CYTOSINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SODIUM CHANNEL NAV1.1; THYMINE; SCN1A PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DNA SEQUENCE; FEMALE; GENDER; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCN1A GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO RECURRENCE; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; AGED; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEXUAL DEVELOPMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SEX CHARACTERISTICS;

EID: 84897460495     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.21     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. CA cancer statistics, 2013. Cancer J Clin 2013; 63: 11-30.
2. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797.
3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109.
4. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51: 503-507.
5. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
6. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
7. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
8. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-2367.
9. Benhaim L, Labonte MJ, Lenz HJ. Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives. Scand J Gastroenterol 2012; 47: 325-339.
10. Ekberg J, Adams DJ. Neuronal voltage-gated sodium channel subtypes: key roles in inflammatory and neuropathic pain. Int J Biochem Cell Biol 2006; 38: 2005-2010.
11. Camerino DC, Desaphy JF, Tricarico D, Pierno S, Liantonio A. Therapeutic approaches to ion channel diseases. Adv Genet 2008; 64: 81-145.
12. Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I, Alfaro A, Berumen J et al. Overexpression of NaV 1. 6 channels is associated with the invasion capacity of human cervical cancer. Int J Cancer 2012; 130: 2013-2023.
13. Diss JK, Stewart D, Pani F, Foster CS, Walker MM, Patel A et al. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis 2005; 8: 266-273.
14. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 2005; 11: 5381-5389.
15. Gao R, Shen Y, Cai J, Lei M, Wang Z. Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer. Oncol Rep 2010; 23: 1293-1299.
16. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T et al. Voltage-gated Na channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res 2010; 70: 6957-6967.
17. Diaz D, Delgadillo DM, Hernández-Gallegos E, Raḿrez- Doḿnguez ME, Hinojosa LM, Ortiz CS et al. Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer. J Cell Physiol 2007; 210: 469-478.
18. Roger S, Rollin J, Barascu A, Besson P, Raynal PI, Iochmann S et al. Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. Int J Biochem Cell Biol 2007; 39: 774-786.
19. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
20. Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M. 5-fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene advance online publication, 29 October 2012 (e-pub ahead of print).
21. Thompson CH, Kahlig KM, George Jr. AL. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia 2011; 52: 1000-1009.
22. Le Gal F, Salzmann A, Crespel A, Malafosse A. Replication of association between a SCN1A splice variant and febrile seizures. Epilepsia 2011; 52: e135-e138.
23. Schlachter K, Gruber-Sedlmayr U, Stogmann E, Lausecker M, Hotzy C, Balzar J et al. A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures. Neurology 2009; 72: 974-978.
24. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol 2009; 68: 214-220.
25. Nagashima F, Zhang W, Yang D, Gordon M, Schultheis A, Fazzone W et al. Polymorphism in sodium-channel alpha 1-subunit (SCNIA) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin. J Clin Oncol (Meeting Abstracts) 2006; 24 (18 Suppl): 3533.
26. Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F et al. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 2011; 12: 27-39.
27. Brackenbury WJ. . Voltage-gated sodium channels and metastatic disease. Channels (Austin) 2012; 6: 352-361.
28. Ferlitsch M, Reinhart K, Pramhas S, Wiener C, Gal O, Bannert C et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011; 306: 1352-1358.
29. Nguyen SP, Bent S, Chen YH, Terdiman JP. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 676-681e1-3.
30. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009; 15: 6391-6397.
31. Koo JH, Jalaludin B, Wong SK, Kneebone A, Connor SJ, Leong RW. Improved survival in young women with colorectal cancer. Am J Gastroenterol 2008; 103: 1488-1495.
32. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
33. Cho YK, Kim HC, Kim SH, Park JH, Yun HR, Cho YB et al. Location-related differences in sporadic microsatellite unstable colorectal cancer. Dig Liver Dis 2010; 42: 611-615.
34. Kim YH, Min BH, Kim SJ, Choi HK, Kim KM, Chun HK et al. Difference between proximal and distal microsatellite-unstable sporadic colorectal cancers: analysis of clinicopathological and molecular features and prognoses. Ann Surg Oncol 2010; 17: 1435-1441.
35. Fernández-Contreras ME, Sánchez-Hernández JJ, Guijarro M, Gisbert JP, Rivas N, Garća de Paredes ML et al. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol Rep 2010; 23: 1393-1400.
36. Pellegrini P, Contasta I, Del Beato T, Ciccone F, Berghella AM. Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer. Clin Dev Immunol 2011; 2011: 819724.
37. Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E et al. Gender influences the class III and V b-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 2012; 18: 2964-2975.
38. Tadić A, Baskaya O, Victor A, Lieb K, Höppner W, Dahmen N. Association analysis of SCN9A gene variants with borderline personality disorder. J Psychiatr Res 2008; 43: 155-163.
39. Blechschmidt S, Haufe V, Benndorf K, Zimmer T. . Voltage-gated Na channel transcript patterns in the mammalian heart are species-dependent. Prog Biophys Mol Biol 2008; 98: 309-318.
40. Lowe JS, Stroud DM, Yang T, Hall L, Atack TC, Roden DM. Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res 2012; 95: 300-307.
41. Fraser SP, Ozerlat-Gunduz I, Onkal R, Diss JK, Latchman DS, Djamgoz MB. Estrogen and non-genomic upregulation of voltage-gated Na() channel activity in MDA-MB-231 human breast cancer cells: role in adhesion. J Cell Physiol 2010; 224: 527-539.
42. Chen SZ, Jiang M, Zhen YS. . HERG K channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol 2005; 56: 212-220.
43. Andrikopoulos P, Fraser SP, Patterson L, Ahmad Z, Burcu H, Ottaviani D et al. Angiogenic functions of voltage-gated Na channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling. J Biol Chem 2011; 286: 16846-16860.
44. Uysal-Onganer P, Djamgoz MB. Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel. Mol Cancer 2007; 6: 76.